Mehta Rajat
Known title: EVP, GBL Commercial OperationsCIK: 0002081681
Associated companies
Transaction History
| BIO | ▲ Buy | Option Exercise | 456 | $0 | 9/5/2026 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 233 | $90K | 9/5/2026 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,370 | $0 | 9/5/2026 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 504 | $195K | 9/5/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth
The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.